ZVRA vs. IOVA, PRAX, GLPG, WVE, APGE, EVO, IRON, ARQT, AMPH, and IMCR
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Evotec (EVO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.
Zevra Therapeutics vs.
Iovance Biotherapeutics (NASDAQ:IOVA) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
Iovance Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500.
In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 6 mentions for Iovance Biotherapeutics and 5 mentions for Zevra Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.65 beat Zevra Therapeutics' score of 0.37 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 12.1% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Iovance Biotherapeutics currently has a consensus target price of $21.07, indicating a potential upside of 264.56%. Zevra Therapeutics has a consensus target price of $21.57, indicating a potential upside of 180.88%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Zevra Therapeutics.
Iovance Biotherapeutics received 534 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 74.34% of users gave Iovance Biotherapeutics an outperform vote.
Zevra Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Zevra Therapeutics has a net margin of -342.63% compared to Iovance Biotherapeutics' net margin of -451.25%. Iovance Biotherapeutics' return on equity of -58.43% beat Zevra Therapeutics' return on equity.
Summary
Iovance Biotherapeutics beats Zevra Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ZVRA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ZVRA Stock Alerts